Health Sciences

In a new effort, researchers from the University of Pennsylvania and Baylor College of Medicine have used advanced imaging technology to fill in details about the underlying cause of canine diabetes, which until now has been little understood.

Health care has much to learn from innovative high-tech companies, but not in the way most people think, according to a Perspective published today in the New England Journal of Medicineand authored by innovation experts from the Perelman School of Medicine and the

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicineat the University of P

Tumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different organs.

The immune system not only responds to infections and other potentially problematic abnormalities in the body, it also contains a built-in brake in the form of regulatory T cells, or Tregs. Tregs ensure that inflammatory responses don’t get out of hand and do damage. In autoimmune diseases, sometimes these Treg cells don’t act as they should.

Tray tables, bed rails, light switches, and toilets: All are common vectors for swapping germs between patients and health care workers.

A large randomized clinical trial of an emergency department (ED)-based program aimed at reducing incidents of excessive drinking and partner violence in women did not result in significant improvements in either risk factor, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania

Moles are benign tumors found on the skin of almost every adult. Scientists have known for years that a mutation in the BRAF gene makes them start growing, but until now haven’t understood why they stop.

esults of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin.

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don’t yet have the full picture of how these cancers originate and spread.